• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Karyopharm - oncology

Quote








anonymous said:
RP is an odd choice for sure. He was the “CEO” of Ipsen NA which is basically a zone VP and not the real ceo. Inflated title for sure. It would have been great to bring in a CEO who has actually executed deals that we are in search/need of. Lastly I was on the Kyprolis team at Onyx/Amgen and RP had little to no real hands on responsibility for Kyprolis. All the heavy lifting was done well before the acquisition and RP wasn’t around all that long with Kyprolis under his watch and lastly it didn’t do well when it was.
Click to expand...

Find out where this leads to understand the board’s logic. Having someone with no strategic ability or insight doesn’t matter too much if you don’t care about the long-term. If your goal is just to get the company sold and max the acquisition price when it goes in the block then you just need a person with a few tactical skills who can squeeze the P&L.
 




anonymous said:
Find out where this leads to understand the board’s logic. Having someone with no strategic ability or insight doesn’t matter too much if you don’t care about the long-term. If your goal is just to get the company sold and max the acquisition price when it goes in the block then you just need a person with a few tactical skills who can squeeze the P&L.
Click to expand...

after 2 years thats all i want from this pos
 




anonymous said:
Find out where this leads to understand the board’s logic. Having someone with no strategic ability or insight doesn’t matter too much if you don’t care about the long-term. If your goal is just to get the company sold and max the acquisition price when it goes in the block then you just need a person with a few tactical skills who can squeeze the P&L.
Click to expand...


Ok...unfortunately we didn’t hire that guy.
 




anonymous said:
Ok...unfortunately we didn’t hire that guy.
Click to expand...

Agreed. Many of us know RP and he is not the investment banker deal maker. He’s a commercial guy who climbed the ranks which is commendable. Many of us don’t care for his narcissist personality, but at this point it doesn’t really matter. We needed a deal maker and if that was the endgame we chose the wrong guy. If anything this may signal that KPTI is in it for the long game. You don’t bring in a “commercial guy” to broker a buy out you bring in CFO/Investment bankers in...we went the other way on this one.
 




anonymous said:
Agreed. Many of us know RP and he is not the investment banker deal maker. He’s a commercial guy who climbed the ranks which is commendable. Many of us don’t care for his narcissist personality, but at this point it doesn’t really matter. We needed a deal maker and if that was the endgame we chose the wrong guy. If anything this may signal that KPTI is in it for the long game. You don’t bring in a “commercial guy” to broker a buy out you bring in CFO/Investment bankers in...we went the other way on this one.
Click to expand...

Narcissist is a clinical way to say arrogant prick. We won’t even talk about the Peter Principle.
 








anonymous said:
long run???? this place is bleeding cash every quarter. The science and drug should beworth 1.5 to 2 billion.....sell this pos to a company where selinexor is 2/3 product
Click to expand...


You think the buyout valuation of KPTI is 2x/3x current mkt cap? Man send me what you are smoking...I don’t disagree that we are hemorrhaging cash but if pulling off a deal was the near term goal they would have brought in a different CEO who has experience in making these deals happen. We did not. RP was brought and more accurately MK was ousted because of the belief, which looks to be accurate, is he is not equipped to run a commercial organization. The rationale is we are not executing commercial well enough to drive revenue and RO is the guy to do it.

Lastly, there are other SINE’s in development that could be purchased if a company really wants in on that market.

No need to pay $1.5B for one.
 








anonymous said:
You have to be dam desperate to take this job:

patient's will have received 4 very highly regarded MM drugs, be refractory to two of those, and when you think that sucks, they also have to be refractory to Anti CD38 .
LOL so you clinical sell will be with a drug essentially 5th line?? Yikes shoot my brains out.

Without being mean, this is truly the walking dead. Very low population to which the length of time on Karyopharm's drug is at best a month or two. You might get 3 out of 100 pts that go longer than 6 mos.

They better be paying 190K base because anybody with MM experience won't touch this position.

Watch you won't making any bonus dollars because their goals will be sky high for a drug where the median, yes median therapies received is an eye popping 7. YES 7.
My gosh!!!!

No wonder it took so long to do the studies...not many of these patients laying around and at what point after all the drugs ppl took with MM to they simply give up?
Click to expand...

Posts don’t age much better than this.
 








The company is valued at about 650 after today. The drug will do around around 100 million with the expanded MM label. It only takes a couple a** hole physicians to add it in to grow even modestly when the drug has under performed. So yeah with a bean counter to wring excess costs and 15 times revenue I think this company could get 1.5 billion and get rid of this piece of shit with some result with long term shareholders to get close to break even.
 




anonymous said:
The company is valued at about 650 after today. The drug will do around around 100 million with the expanded MM label. It only takes a couple a** hole physicians to add it in to grow even modestly when the drug has under performed. So yeah with a bean counter to wring excess costs and 15 times revenue I think this company could get 1.5 billion and get rid of this piece of shit with some result with long term shareholders to get close to break even.
Click to expand...

Not a chance...love the optimism, but like I said before there are other SINE’s in development and those could be bought for a lot less than $1B. 15 times current revenue will not happen.
 




Couldnt they get any value from other assets in pipeline such as Endo coming in Q4. Wouldn’t a positive phase 3 readout add to the MC even assuming doing 100m a year in MM which is kinda conservative.
 




anonymous said:
Couldnt they get any value from other assets in pipeline such as Endo coming in Q4. Wouldn’t a positive phase 3 readout add to the MC even assuming doing 100m a year in MM which is kinda conservative.
Click to expand...

Maybe, but the market is flooded right now now with early Phase drugs from small shops. There are bargains out there for speculators...1-2B is pricey and less expensive deals seem to be what is hot right now. That and more development arrangements...so less full buyouts to mitigate the risk.
 




Yes,
That has been happening for past number of years. I don’t think it’s feasible for Kpti to go alone. What can RP do to drastically boost revs in time to head off a secondary next year?? Even euro partnership won’t be enough to muddle through. It seems that either a full out partnership across the board more like a strategic
Alliance or a BO is on horizon.
 








anonymous said:
This piece of shit at 1 billion plus would be a drop in the bucket to other MM players....Im optimistic/delusional cause I should never have bought this POS
Click to expand...


Yeah it may be a drop in the bucket for many companies, however it get's the buyer very little in terms of a revenue stream, and pipeline

Stemline, who was acquired by the Menarini Group for $677M has an XPO1 drug in development, and a deeper pipeline than ours and they were brining in about $50M in 2019 with ELZONRIS. - couldn't find 2020 revenue for it. If you use that as a litmus it's hard to see how we get bought for much more than that, let alone double. Guessing Menarini would sell their XPO1 off for far less than $1B...since they bought all of Stemline's assets for $677M.

Point being if you really want an XPO1 there are less expensive options out there than paying a super premium for KPTI's.
 




anonymous said:
Yes,
That has been happening for past number of years. I don’t think it’s feasible for Kpti to go alone. What can RP do to drastically boost revs in time to head off a secondary next year?? Even euro partnership won’t be enough to muddle through. It seems that either a full out partnership across the board more like a strategic
Alliance or a BO is on horizon.
Click to expand...

RP doesn’t have the ability to and won’t do anything.
 




Top Bottom
Back
Quote